HK Stock Market Move | XIAOMI-W(01810) rose more than 5% and released the mobile end Agent product "Xiaomi miclaw".
Xiaomi Group-W (01810) surged more than 5%, as of the time of drafting, it rose by 5.22% to HK$33.88, with a turnover of HK$5.714 billion.
Xiaomi-W (01810) rose more than 5%, rising by 5.22% as of press time, to 33.88 Hong Kong dollars, with a turnover of 5.714 billion Hong Kong dollars.
On the news front, on March 6, Xiaomi released the mobile end Agent product "Xiaomi Miclaw". Xiaomi's official technical Weibo post stated: "Based on the AI interaction test product Xiaomi Miclaw built on the Xiaomi MiMo large model, today officially started small-scale closed beta testing. Compared with traditional AI assistants, Xiaomi Miclaw has four levels of capabilities: system low-level capabilities, personal context understanding, ecological interconnection, and self-evolution. Xiaomi Miclaw is a small step in our exploration of Agent, and this closed beta test is not publicly recruiting, using an invitation system, with the first batch supporting the Xiaomi 17 series models."
According to the Securities Times, Lei Jun revealed that Xiaomi will invest 200 billion yuan in the next five years to promote hardcore technological innovation. Guosheng recently issued a research report indicating that Xiaomi's AI progress and multi-terminal collaborative ecosystem are expected to lead the future hardware entry. The bank believes that Xiaomi Group, as a leading industry share, outstanding high-end enterprise, after facing short-term disruptions in the industry environment, is expected to have stronger long-term relative competitiveness.
Related Articles

HK Stock Market Move | U-PRESID China (00220) closes up over 6%, annual net profit exceeds 2 billion, Goldman Sachs says adjusted net profit exceeds expectations.

Hebei Changshan Biochemical Pharmaceutical (300255.SZ): Enoxaparin Sodium Injection Obtains Drug Registration Certificate in Tajikistan.

Shenyang Xingqi Pharmaceutical(300573.SZ) obtained a drug registration certificate.
HK Stock Market Move | U-PRESID China (00220) closes up over 6%, annual net profit exceeds 2 billion, Goldman Sachs says adjusted net profit exceeds expectations.

Hebei Changshan Biochemical Pharmaceutical (300255.SZ): Enoxaparin Sodium Injection Obtains Drug Registration Certificate in Tajikistan.

Shenyang Xingqi Pharmaceutical(300573.SZ) obtained a drug registration certificate.

RECOMMEND





